Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

21. Causes and risk factors: Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence

Causes and risk factors: Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Childhood comorbidity and parental mental health problems appear to be associated with ADHD persistence Article Text Electronic pages Causes and risk

Evidence-Based Mental Health2017

22. Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review

Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review Article Text Clinical reviews Pharmacological and non-pharmacological treatment of adults with ADHD: a meta-review Franco De Crescenzo , Samuele Cortese , , Nicoletta Adamo , Luigi Janiri Statistics from Altmetric.com Introduction

Evidence-Based Mental Health2017

23. Medications for attention deficit hyperactivity disorder (ADHD) in children

Medications for attention deficit hyperactivity disorder (ADHD) in children

DynaMed Plus2017

24. Attention deficit hyperactivity disorder (ADHD) in children and adolescents

Attention deficit hyperactivity disorder (ADHD) in children and adolescents

DynaMed Plus2017

27. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology 27760867 2016 10 20 2017 05 12 2017 05 12 1526-632X 87 22 2016 Nov 29 Neurology Neurology Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. 2375 (...) -2379 To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD). We identified relevant studies and classified them using American Academy of Neurology criteria. Two Class I studies assessing the ability of EEG theta/beta power ratio and EEG frontal beta power to identify patients with ADHD correctly identified 166 of 185 participants. Both studies evaluated theta/beta power ratio and frontal beta power

EvidenceUpdates2016

28. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial.

Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. 27790334 2016 10 28 2017 02 24 8 9 2016 Sep Electronic physician Electron Physician Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. 2840-2848 (...) Attention-deficit hyperactivity disorder (ADHD) is a common psychiatric disease with a worldwide pooled prevalence of 5.29%. To compare the efficacy of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among 3- to 6-year-old children. In a 6-week double-blind clinical trial, the efficacy of Risperidone 0.5-2 mg with a dose of maximum Haloperidol 0.075 mg/kg was assessed in 39 children aged 3-6 years. This study was conducted at the Golestan Psychiatric Clinic (Ahvaz, Iran). Measurement

Electronic physician2016 Full Text: Link to full Text with Trip Pro

29. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. OBJECTIVE: To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. DESIGN: Self controlled case series analysis. SETTING: Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South (...) exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. CONCLUSION: The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low

BMJ2016

30. Pharmacologic Management of Patients with ADHD: Review of Guidelines

Pharmacologic Management of Patients with ADHD: Review of Guidelines Pharmacologic Management of Patients with ADHD: Review of Guidelines | CADTH.ca Find the information you need Pharmacologic Management of Patients with ADHD: Review of Guidelines Pharmacologic Management of Patients with ADHD: Review of Guidelines Published on: March 18, 2016 Project Number: RC0759-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What (...) are the evidence-based guidelines for the pharmacologic management of ADHD in children, adolescents, and adults? Key Message Stimulant drugs are the first-choice pharmacological treatment for ADHD in children, adolescents, and adults. Atomoxetine is the preferred initial choice of treatment when there is a risk that stimulant drugs may be abused/misused or diverted. Atomoxetine is also the recommended drug of choice when stimulant ADHD drugs are contra-indicated, ineffective, or poorly tolerated

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

31. Guanfacine hydrochloride (Intuniv) - treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents

Guanfacine hydrochloride (Intuniv) - treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents

Scottish Medicines Consortium2016

32. Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD)

Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway (...) Close Quality and Knowledge Close More topics Close The Norwegian Institute of Public Health, Knowledge Centre was commissioned by “Bestillerforum RHF” to undertake a rapid review of research on Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD). Methods We conducted a systematic search in nine medical, social sciences and health related databases to identify relevant research publications on adults with ADHD and psychoeducative treatment. The search was conducted

Norwegian Institute of Public Health2016

33. ADHD in Children and Adolescents

ADHD in Children and Adolescents ADHD in Children and Adolescents -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline ADHD in Children and Adolescents ADHD: Clinical Practice Guidelines for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (Reaffirmed, May 2016) The guideline on ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment (...) of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents was developed by the American Academy of Pediatrics (AAP) and endorsed by the American Academy of Family Physicians (AAFP). Key Recommendations Any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity should be evaluated for ADHD. The diagnosis of ADHD should be based on the criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, with information

American Academy of Family Physicians2016

34. Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis

Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share November 29, 2016 ; 87 (22) Special Article Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis Report of the Guideline Development (...) .), University of California at Los Angeles. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis David Gloss , Jay K. Varma , Tamara Pringsheim , Marc R. Nuwer Neurology Nov 2016, 87 (22) 2375-2379; DOI: 10.1212/WNL.0000000000003265 Citation Manager Formats Downloads 1955 Share Abstract Objective: To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD). Methods: We identified relevant studies

American Academy of Neurology2016

35. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality?

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ O J Storebø , , , M Zwi , H B Krogh , , C R Moreira-Maia , M Holmskov , , D Gillies

Evidence-Based Mental Health2016

36. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Tobias Banaschewski , Jan Buitelaar , , Celine S L Chui , David Coghill , Samuele Cortese , , Emily Simonoff

Evidence-Based Mental Health2016

37. Outcomes: Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity

Outcomes: Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Article Text Electronic pages Outcomes Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Joel Nigg Statistics from Altmetric.com No Altmetric data available for this article. ABSTRACT FROM: Cortese S

Evidence-Based Mental Health2016

40. Atomoxetine (Strattera) - treatment of attention-deficit/hyperactivity disorder (ADHD)

Atomoxetine (Strattera) - treatment of attention-deficit/hyperactivity disorder (ADHD) Published 07 December 2015 Product Update atomoxetine oral solution 4mg/mL (Strattera ® ) SMC No. (1107/15) Eli Lilly and Company Limited 06 November 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following (...) an abbreviated submission atomoxetine oral solution (Strattera ® ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM

Scottish Medicines Consortium2015